Search Videos by Topic or Participant
Browse by Series:

Biomarkers for Bevacizumab in Ovarian Cancer

Panelists:Robert L. Coleman, MD, MD Anderson Cancer Center; Thomas Herzog, MD, University of Cincinnati Cancer Institute; Bradley J. Monk, MD, University of Arizona Cancer Center; Angeles Alvarez Secord, MD, Duke University School of Medicine; James Tate Thigpen, MD, University of Mississippi School of Medicine
Published: Tuesday, Jul 21, 2015


Frontline management of ovarian cancer typically includes 6 cycles of chemotherapy with paclitaxel, carboplatin, and bevacizumab followed by bevacizumab maintenance therapy until disease progression, states Robert L. Coleman, MD. It remains unclear whether frontline bevacizumab should be continued indefinitely, specifically if patients are not having symptoms from their cancer in the maintenance setting, comments Angeles Alvarez Secord, MD.

A retrospective analysis of data from the ICON7 study revealed a potential biomarker that could be used to tailor therapy. In this investigation, patients with high-grade serous ovarian cancer with an immune gene upregulation and angiogenic gene repression experienced worse outcomes with the addition of bevacizumab. For patients with this signature (41%), the addition of bevacizumab conferred a worse PFS (HR = 1.73) and OS (HR = 2.00) compared with chemotherapy alone. Women in this immune molecular subgroup had degradation in survival when treated with bevacizumab, explains Thomas Herzog, MD. This information reveals that not only does bevacizumab therapy not benefit this group but may cause harm from toxicity and cost.

In addition to detecting those unlikely to respond, it is also critical to find patients who are appropriate for treatment with bevacizumab, adds Secord. Clinical trial have shown indicators that may help identify individuals most likely to benefit from bevacizumab, explains Secord, such as information about patients with ascites. The use of this data in combination with information from molecular biomarkers and tissue-based studies could help develop a tool that selects patients for bevacizumab treatment, says Secord.
Slider Left
Slider Right


Frontline management of ovarian cancer typically includes 6 cycles of chemotherapy with paclitaxel, carboplatin, and bevacizumab followed by bevacizumab maintenance therapy until disease progression, states Robert L. Coleman, MD. It remains unclear whether frontline bevacizumab should be continued indefinitely, specifically if patients are not having symptoms from their cancer in the maintenance setting, comments Angeles Alvarez Secord, MD.

A retrospective analysis of data from the ICON7 study revealed a potential biomarker that could be used to tailor therapy. In this investigation, patients with high-grade serous ovarian cancer with an immune gene upregulation and angiogenic gene repression experienced worse outcomes with the addition of bevacizumab. For patients with this signature (41%), the addition of bevacizumab conferred a worse PFS (HR = 1.73) and OS (HR = 2.00) compared with chemotherapy alone. Women in this immune molecular subgroup had degradation in survival when treated with bevacizumab, explains Thomas Herzog, MD. This information reveals that not only does bevacizumab therapy not benefit this group but may cause harm from toxicity and cost.

In addition to detecting those unlikely to respond, it is also critical to find patients who are appropriate for treatment with bevacizumab, adds Secord. Clinical trial have shown indicators that may help identify individuals most likely to benefit from bevacizumab, explains Secord, such as information about patients with ascites. The use of this data in combination with information from molecular biomarkers and tissue-based studies could help develop a tool that selects patients for bevacizumab treatment, says Secord.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x